Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans

Open access

Abstract

The accurate assessment of AAV-specific pre-existing humoral immunity due to natural viral infection is critical for the efficient use of clinical gene therapy. The method described in the present study applies equivalent infection conditions to each AAV serotype (AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, and AAVAnc80L65). In the current study, we validated the assay by assessing AAV-neutralizing antibody titers in a limited cohort of random human donors and well-established preclinical large animal models, including dogs and non-human primates (NHPs). We achieved a rapid and accurate evaluation of neutralizing titers for each individual subject that can be used for clinical enrollment based on specific AAV serotypes and individualized selection of the most suitable AAV serotype for each specific patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines11020523

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic outline of the experimental procedure neutralizing antibody assay.
Figure 1 Schematic outline of the experimental procedure neutralizing antibody assay.CC BY · PubMed Central
Figure 2 Screening of human samples for the presence of anti-AAV NAB. Human serum samples (n = 12) were screened for the presence of NAB against 10 AAV serotypes. For the initial screening, tested serum samples were used at dilutions 1:2, 1:8, and 1:32, and FBS was used as a diluent. The data are presented as a percentage of luciferase activity in the presence of the corresponding dilution of tested samples compared to the control (AAV serotype X- Luc mixed with diluent only). Each column is a mean ± SD in triplicate. Statistically significant differences are indicated as p * < 0.05, p ** < 0.01 vs. the uninhibited control for each AAV serotype.
Figure 2 Screening of human samples for the presence of anti-AAV NAB. Human serum samples (n = 12) were screened for the presence of NAB against 10 AAV serotypes. For the initial screening, tested serum samples were used at dilutions 1:2, 1:8, and 1:32, and FBS was used as a diluent. The data are presented as a percentage of luciferase activity in the presence of the corresponding dilution of tested samples compared to the control (AAV serotype X- Luc mixed with diluent only). Each column is a mean ± SD in triplicate. Statistically significant differences are indicated as p * < 0.05, p ** < 0.01 vs. the uninhibited control for each AAV serotype.CC BY · PubMed Central
Figure 3 The determination of anti-AAV NAB titers in selected human serum samples. Human samples with titers higher than 1:32 against particular AAV serotypes were re-evaluated at dilutions ranging from 1:2 to 1:4096, and inhibitory curves were built to determine the titers. Since the NAB titers for AAV5 and AAV8 in all tested human samples were lower than 1:32, an assay was performed for several random samples as a proof of concept. The Y-axis presents chemiluminescence intensity units of the reporter luciferase encoded by AAV. NAB titers were determined as a dilution of the serum sample at which 50% of the fluorescence signal was obstructed. The representative inhibitory curve for each analyzed AAV serotype is shown.
Figure 3 The determination of anti-AAV NAB titers in selected human serum samples. Human samples with titers higher than 1:32 against particular AAV serotypes were re-evaluated at dilutions ranging from 1:2 to 1:4096, and inhibitory curves were built to determine the titers. Since the NAB titers for AAV5 and AAV8 in all tested human samples were lower than 1:32, an assay was performed for several random samples as a proof of concept. The Y-axis presents chemiluminescence intensity units of the reporter luciferase encoded by AAV. NAB titers were determined as a dilution of the serum sample at which 50% of the fluorescence signal was obstructed. The representative inhibitory curve for each analyzed AAV serotype is shown.CC BY · PubMed Central
Figure 4 Anti-AAV NAB assay for non-human primate (NHP) samples. (A) Screening for the presence of NABs against 10 AAV serotypes in NHP serum (n = 6). Samples were screened as described for human samples in Figure 2 at dilutions of 1:2, 1:8, and 1:32. Data are presented as the mean ± SD in triplicate. Statistically significant differences are indicated as p * < 0.05, p ** < 0.01 vs. uninhibited control for each AAV serotype. (B) NAB titers for AAV5 in NHP sample #4 and AAV9 in NHP sample #5 determined at dilutions ranging from 1:2 to 1:4096.
Figure 4 Anti-AAV NAB assay for non-human primate (NHP) samples. (A) Screening for the presence of NABs against 10 AAV serotypes in NHP serum (n = 6). Samples were screened as described for human samples in Figure 2 at dilutions of 1:2, 1:8, and 1:32. Data are presented as the mean ± SD in triplicate. Statistically significant differences are indicated as p * < 0.05, p ** < 0.01 vs. uninhibited control for each AAV serotype. (B) NAB titers for AAV5 in NHP sample #4 and AAV9 in NHP sample #5 determined at dilutions ranging from 1:2 to 1:4096.CC BY · PubMed Central
Figure 5 Anti-AAV NAB assay for dog samples. (A) Screening for the presence of NABs against 10 AAV serotypes in dog serum samples (n = 6). Samples were screened as described above in Figure 2 and Figure 4 at dilutions of 1:2, 1:8, and 1:32. Data are presented as the mean ± SD in triplicate. Statistically significant differences are indicated as p * < 0.05, p ** < 0.01 vs. the control. (B) NAB titer for AAV1 and AAV2 in dog sample #6 determined at dilutions ranging from 1:2 to 1:4096.
Figure 5 Anti-AAV NAB assay for dog samples. (A) Screening for the presence of NABs against 10 AAV serotypes in dog serum samples (n = 6). Samples were screened as described above in Figure 2 and Figure 4 at dilutions of 1:2, 1:8, and 1:32. Data are presented as the mean ± SD in triplicate. Statistically significant differences are indicated as p * < 0.05, p ** < 0.01 vs. the control. (B) NAB titer for AAV1 and AAV2 in dog sample #6 determined at dilutions ranging from 1:2 to 1:4096.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Cited by

See all 5

Metadata

Authors
Kuoch, H., Krotova, K., Graham, M. L., Brantly, M. L., & Aslanidi, G.
Affiliations
  • University of Minnesota (US)
  • University of Florida (US)
Corresponding author
Aslanidi, George
Venue
Biomedicines
Publisher
MDPI AG
Published
2023-02-11
Volume
11
Issue
2
Pages
523
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4320491185
Cited by
5
References
96
Citations by year
2026: 1 · 2024: 3 · 2023: 1
FWCI
0.83
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • NIH (R01HL131586, FD007483)
  • FDA/CEBR (R01HL131586, FD007483)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
Keywords
adeno-associated virus, AAV serotypes, neutralizing antibodies, humoral immunity, pre-existing immunity, gene therapy, AAV8, AAV9, non-human primates, dogs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans. https://app.cochat.ai/papers/10.3390/biomedicines11020523
The paper
Kuoch, H., Krotova, K., Graham, M. L., Brantly, M. L., & Aslanidi, G. (2023). Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans. Biomedicines. https://doi.org/10.3390/biomedicines11020523

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.